12/12/2018
Positive news regarding Rimegepant and itโs long term safety as a new acute medication for migraine. Study participants were allowed to take medication for attacks once daily for up to a year.
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced initial positive results from its...